Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)

Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be made. Muscle wasting in cancer is an important and independent predictor of progressive functional impairment, decreased quality of li...

Descripción completa

Detalles Bibliográficos
Autores principales: Crawford, Jeffrey, Prado, Carla M. M., Johnston, Mary Ann, Gralla, Richard J., Taylor, Ryan P., Hancock, Michael L., Dalton, James T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Integrative Care (C Lammersfeld, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853438/
https://www.ncbi.nlm.nih.gov/pubmed/27138015
http://dx.doi.org/10.1007/s11912-016-0522-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853438/
https://www.ncbi.nlm.nih.gov/pubmed/27138015
http://dx.doi.org/10.1007/s11912-016-0522-0

Ejemplares similares